Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.
Aug 2022 | From Akero Therapeutics
Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health
Jun 2022 | From Akero Therapeutics
Efruxifermin (EFX), a long-acting FGF21 analog as a therapy for NASH
Nov 2021 | From Akero Therapeutics
Characterization of Histologic Patterns of Improvement Following Treatment With Efruxifermin (EFX) in NASH Patients With Fibrosis
Jul 2021 | FROM AKERO THERAPEUTICS
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

